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Abstract
Background: Although several studies suggest that genetic factors are associated with human UTI susceptibility, the role of
DNA variation in regulating early in vivo urine inflammatory responses has not been fully examined. We examined whether
candidate gene polymorphisms were associated with altered urine inflammatory profiles in asymptomatic women with or
without bacteriuria.
Methodology: We conducted a cross-sectional analysis of asymptomatic bacteriuria (ASB) in 1,261 asymptomatic women
ages 18-49 years originally enrolled as participants in a population-based case-control study of recurrent UTI and
pyelonephritis. We genotyped polymorphisms in CXCR1, CXCR2, TLR1, TLR2, TLR4, TLR5, and TIRAP in women with and
without ASB. We collected urine samples and measured levels of uropathogenic bacteria, neutrophils, and chemokines.
Principal Findings: Polymorphism TLR2_G2258A, a variant associated with decreased lipopeptide-induced signaling, was
associated with increased ASB risk (odds ratio 3.44, 95%CI; 1.65–7.17). Three CXCR1 polymorphisms were associated with
ASB caused by gram-positive organisms. ASB was associated with urinary CXCL-8 levels, but not CXCL-5, CXCL-6, or sICAM-1
(P#0.0001). Urinary levels of CXCL-8 and CXCL-6, but not ICAM-1, were associated with higher neutrophil levels (P#0.0001).
In addition, polymorphism CXCR1_G827C was associated with increased CXCL-8 levels in women with ASB (P=0.004).
Conclusions: TLR2 and CXCR1 polymorphisms were associated with ASB and a CXCR1 variant was associated with urine
CXCL-8 levels. These results suggest that genetic factors are associated with early in vivo human bladder immune responses
prior to the development of symptomatic UTIs.
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Introduction
Over 100 years ago, scientists observed that bacteriuria could
occur in the absence of urinary tract inflammation [1]. This simple
fact suggests that although bacteria are capable of inducing
bladder inflammation, their presence alone may not necessarily be
sufficient to produce an inflammatory response. Thus, bladder
inflammation may be regulated by variation in the host response.
Although urine is usually sterile, bacteriuria at $10
5 colony-
forming units (cfu)/mL is found in approximately 5–10% of
healthy, asymptomatic pre-menopausal women [2,3,4]. Quantifi-
cation of bacteriuria was established over 50 years ago as a means
to differentiate true bladder bacteriuria from contamination with
perineal flora [1,5,6]. Several studies demonstrated that asymp-
tomatic bacteriuria (ASB) at $10
5 cfu/ml is associated with an
increased risk of developing a symptomatic urinary tract infection
(UTI) [2,3,4]. Despite its prevalence, the pathogenesis of ASB and
risk factors for progression to acute UTI are poorly understood
[2,4,7,8]. Similar to acute UTI, ASB has been associated with
behavioral risk factors such as sexual activity and contraceptive
choice (diaphragm and spermicide use) [4,9]. However, the
majority of women have no obvious functional or anatomic risk
factors predisposing them to ASB, which suggests that genetic
factors may modulate the risk of acquiring ASB.
After colonization of the urethra and ascent to the bladder,
bacteria bind to glycosphingolipid and glycoprotein receptors on
urinary tract epithelium and are detected by the innate immune
system through pattern recognition receptors such as Toll-like
receptors (TLRs) [10,11]. E. coli, which causes 70–90% of all
uncomplicated UTIs, is recognized by several TLRs, including
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TLRs are located on the cell surface or within organelles such as
phagosomes, where they detect microbial ligands such as flagellin
(TLR5), lipopolysaccharide (LPS) (TLR4), and bacterial lipopep-
tides (TLR1/2/6) [10]. Although previous studies in mice indicate
that TLRs regulate susceptibility to cystitis and pyelonephritis,
TLR modulation of human in vivo bladder immune responses is
poorly understood [11,15,16,17].
After activation, TLRs mediate signaling pathways that
include activation of NF-kB and secretion of chemokines such
as CXCL-8 (also called IL-8) [10,18]. Several clinical studies
have demonstrated CXCL-8 in the urine of individuals with
acute, symptomatic UTI [19,20,21,22,23,24,25,26,27,28]. Neu-
trophils migrate from blood vessels to the bladder or kidneys in
response to CXCL-8, which binds to the CXCR1 and CXCR2
receptors (also called IL-8RA and IL8RB) [29,30]. Mice with
defects in the IL-8 receptor homologue (mIL-8Rh, homologous
to CXCR1 and CXCR2 in humans) are more susceptible to
UTIs [29]. After reaching the bladder lumen, neutrophils bind,
phagocytose, and eliminate the bacteria. In addition to CXCL-
8, several other chemokines are secreted by epithelial cells and
induce neutrophil migration including CXCL-5 (also called
ENA-78 (Epithelial Cell-Derived Neutrophil-Activating Protein-
78)) and CXCL-6 (also called GCP2 (Granulocyte Chemotactic
Protein 2)), which also bind to CXCR1/2 [18]. Additional
chemotactic molecules operate in blood vessels including
sICAM-1 (soluble intercellular adhesion molecule 1), which
binds to the CD11b/CD18 (Mac-1) integrin receptor and
induces transendothelial migration of neutrophils [31]. Togeth-
er, these data suggest that several molecules and inflammatory
pathways are important in neutrophil migration into the bladder
and thus UTI pathogenesis.
A series of studies over several decades indicates that host
genetic factors influence susceptibility to human infections
[32,33,34]. More recent studies suggest an influence of genetics
on susceptibility to UTIs [35,36,37]. In one family study, 15%
of relatives of pyelonephritis-prone children had a UTI history
compared to 3% of relatives of controls [36]. We previously
found that adult women with rUTIo rp y e l o n e p h r i t i sw e r em o r e
likely to have a mother with a UTI history in comparison to
controls [38,39]. Susceptibility to rUTI and/or pyelonephritis in
humans is associated with polymorphisms in the genes for non-
secretor blood group antigens, P1 phenotype, CXCR1, TLR1,
TLR2, TLR4, and TLR5 [37,40,41,42,43,44,45,46,47,48,49].
In addition, reduced expression levels of CXCR1 and CXCR2
on neutrophils was associated with pyelonephritis and recurrent
cystitis, respectively [29,37,50,51]. We recently found associa-
t i o n so fv a r i a n t so fT L R s1 ,4 ,a n d5w ith susceptibility to cystitis
and/or pyelonephritis in a case-control study of adult women
[49]. Studies of genetic variation and ASB have been more
limited, with one previous study demonstrating an association of
SNP TLR2_G2258A with ASB in children [47]. Reduced
expression levels of TLR4 were associated with an increased risk
of ASB [50]. To our knowledge, no studies have examined
whether polymorphisms are associated with bacteriuria or
altered urinary chemokine or neutrophil levels in asymptomatic
adults.
In this study, we examined whether CXCR1, CXCR2, and
TLR pathway polymorphisms are associated with ASB, urinary
chemokines, and neutrophils in a cross-sectional study of adult
women ages 18–49 years with and without a history of recurrent
cystitis or pyelonephritis. Asymptomatic bacteriuria provides an
opportunity to investigate the role of genetic factors in the early
phases of the human in vivo host immune response to bacteria.
Materials and Methods
Study Setting and Participants
The study protocols were approved by the Human Subjects
committees at Group Health Cooperative, the University of
Washington, and Western Institutional Review Board. The study
was conducted at Group Health Cooperative in Seattle,
Washington. Written informed consent was obtained from all
subjects. We performed a cross-sectional study to examine whether
candidate gene polymorphisms are associated with ASB or urine
inflammatory markers in 1261 women. The subjects were enrolled
as part of a case-control study of rUTI and pyelonephritis that has
been previously described [49]. Briefly, we selected potential rUTI
and pyelonephritis cases from the health plan’s automated
databases identified through having received an International
Classification of Diseases (ICD-9) diagnosis code. Recurrent
cystitis (rUTI) case subjects (n=431) were identified based on 3
diagnosed UTI episodes within a 12-month time frame or 2 UTIs
within 6 months (episodes were separated by at least 30 days).
Culture confirmation ($10
3 cfu/mL of a urinary pathogen) or
UTI guideline-related treatment was required for all UTI episodes
in the cluster. Women experiencing previous pyelonephritis
(n=400) were identified through having received a pyelonephritis
ICD-9 diagnosis code and, if they received only outpatient
treatment, a primary diagnosis of pyelonephritis and an accom-
panying culture result of $10
3 cfu/mL of a urinary pathogen or
accompanying antibiotic therapy appropriate for pyelonephritis.
The remainder of the women constituted the potential control
subjects (n=430) with no history of UTIs who were randomly
selected and frequency-matched by case age group (age categories
were 18–29, 30–39, 40–49 years). For these analyses, the 1261
participants, all asymptomatic at their study clinic visits, were
classified into groups of ASB status based on the urine bacterial
counts.
Urine Specimen Collection and Processing
Subjects were asymptomatic at the time of their clinic visits. We
collected a clean-catch midstream urine specimen in a sterile BD
Vacutainer
TM Urine Tube (Becton, Dickinson and Company)
containing a lyophilized preservative including boric acid and
sodium formate. Specimens were stored at room temperature and
transported to the laboratory within 72 hours where they were
inoculated onto blood agar, MacConkey, and CNA plates. Plates
were incubated at 37uC for 48 hours, and organisms were
quantified in colony-forming units (cfu)/ml and further identified
using standard methods [52]. All uropathogens present in
midstream urine at $10
3 cfu/ml were identified and quantified
and E. coli were characterized as beta- or non-hemolytic. A second
urine sample was collected in a sterile container to measure
urinary neutrophil levels with a dipstick assay (Bayer Multistix
Reagent Strips) and reported on a scale of negative, trace, small
(+1), moderate (+2), or large (+3). The trace category was excluded
from the analysis. The negative category was compared to the 3
other values. In addition, 2 mls of urine from the 2
nd collection
were immediately frozen and stored at 270uC for later testing for
IL-6, CXCL-8, CXCL-5, CXCL-6, and sICAM-1 levels. Prior to
testing, specimens were centrifuged at 12,000 RPM for 2 minutes,
and the supernatants were removed for analysis. The supernatant
was subjected to a sandwich ELISA technique (Duoset, R&D
Systems, Minneapolis, MN). Values below the lowest detectable
limit of the assay were replaced as zero (lowest detectable values
for CXCL-8, CXCL-5, CXCL-6, sICAM-1 were 32.5, 16.1, 6.1,
and 6.1 respectively).
Polymorphisms and ASB
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Genomic DNA was purified from peripheral blood by QIAamp
DNA blood kit (Qiagen). For genotyping in the full cohort, we
generated haplotype-tagging SNPs from our sequencing data as
well as publicly available data from the Innate Immunity Program
in Genomic Applications (IIPGA, http://innateimmunity.net/).
For determining haplotype tagging SNPs, we selected polymor-
phisms in the chromosomal region of each gene which represented
the commonly inherited haplotypes (combinations of individual
alleles). Selection criteria were based on linkage disequilibrium
measurements between the polymorphisms [53]. Genotyping was
carried out with a MassARRAY
TM technique (Sequenom) as
previously described [54,55].
Statistical Analyses
Several different exposures and outcomes were assessed in the
analysis. For the primary analysis, polymorphisms of candidate
genes were classified as exposures and ASB or urine inflammatory
markers (chemokines or neutrophils) were treated as the outcomes.
To evaluate the association of genetic polymorphisms with ASB,
we defined 3 outcome groups: no ASB (,10
3 CFU/ml of
uropathogen), medium ASB ($10
3 and ,10
5 CFU/ml of
uropathogen) and high ASB ($10
5 CFU/ml of uropathogen).
We also evaluated ASB as an exposure with urine neutrophils or
chemokines as the outcomes. For these analyses, only cultures with
uropathogens were examined. Cultures with non-uropathogens
(coagulase-negative staphylococci, other gram-negative rods, and
mixed gram-positive flora) were not included in the definition of
ASB. Furthermore, any culture with greater than or equal to
100,000 CFU/ml of coagulase-negative staphylococci, mixed
gram-negative flora, or mixed gram-positive flora was excluded
from the analysis to avoid samples that may have been
contaminated with skin or perineal flora during collection
(n=139 excluded and n=1122 analyzed further). Gram-negative
uropathogens included E. coli non-hemolytic, E. coli b-hemolytic,
Proteus species, Enterobacter species, Klebsiella species, Citrobacter
species, and Morganella morganii. Gram-positive uropathogens
included Enterococcus species, Lactobacillus species, Group B
Streptococcus, Staphylococcus aureus, and S. saprophyticus. In addition
to stratifying by ASB level, we performed subgroup analyses of
ASB caused by gram-negative and gram-positive pathogens.
For the genetic analyses, SNP genotypes (the exposure) and ASB
status or (the outcomes) were examined with an allelic trend test.
In the allelic trend test (also called a log-additive model) common
homozygous genotypes (00) were assigned a value of 0,
heterozygotes (01) a value of 1, and minor homozygous genotypes
(11) a value of 2. Odds ratios and statistical significance values
were then assessed using logistic regression models. We analyzed
the ASB groups separately (medium ASB vs no ASB or high ASB
vs no ASB) and as a combined group (medium + high ASB vs no
ASB). Two-sided testing was used for all comparisons to evaluate
statistical significance, considering a P-value of #0.05 as
significant. To verify that our significant findings were not due
to population admixture, we also performed Caucasian subgroup
analyses. All analyses were performed using the software Hplus or
SAS [56]. Hardy-Weinberg equilibrium (HWE) testing was
performed for all SNP genotypes using Haploview. All SNP
genotypes satisfied Hardy-Weinberg in the Caucasian control
group indicating that there were no genotyping errors or major
effects of population heterogeneity.
Univariate analyses were performed for categorical variables
with a Chi-Square test; Fisher’s exact test was used when the
number of samples in a group was less than 5. The Mann-Whitney
U-test was used to make comparisons of the chemokine levels
between ASB Groups. We expressed the chemokine data as 75th
or 90th percentile values due to the high number of women with
undetectable urinary chemokines. The percent of women with
undetectable chemokine levels was: 32.6% for CXCL-8, 39.1% for
CXCL-5, 39.5% for CXCL-6, and 5.8% for sICAM-1. Chemo-
kine levels were analyzed by genotype for each polymorphism with
an allelic trend test using a general linear model.
While these data were analyzed cross-sectionally, the study
sample was originally selected for a study employing a case-control
methodology, and thus case-control status could potentially
confound the associations of current interest. To address this
issue, we adjusted our analyses for case-control status, finding that
this design variable did not act as a confounder. We also
incorporated an interaction term for case-control status and
the exposures of interest, to assess possible heterogeneity in
associations.
Results
Study Population Characteristics
We used a cross-sectional approach to examine whether
candidate gene polymorphisms were associated with bacteriuria,
urine chemokines, or urine neutrophils. We also examined whether
bacteriuria was associated with chemokine or neutrophil levels.
Midstream voided urines were obtained from 1261 women during
their asymptomatic enrollment clinic visits and used to define the
three groups: no ASB (,10
3 cfu/ml), medium ASB ($10
3 to
,10
5 cfu/ml), or high ASB ($10
5 cfu/ml). The ethnic back-
grounds of women in these 3 groups were similar with a
predominance of a Caucasian background (Caucasian frequency
77.6% in no ASB group, 74.1% in medium ASB group, and 84.8%
in high ASB group (Table 1) The history of co-morbid conditions
and urinary tract procedures was similar except that diabetes was
more common in women with ASB (P#0.01 for those with medium
ASB and P#0.05 for those with high ASB) and bladder or kidney
surgery was more common in those with high ASB (P#0.01)
(Table 1). The predominant organisms were E. coli and Enterococcus
with smaller numbers of various other bacteria (Table 1).
TLR2 and CXCR1 Polymorphisms Are Associated with ASB
We first examined whether polymorphisms in candidate immune
response genes were associated with ASB. We examined 5
polymorphisms in CXCR1, as previous studies have described an
association of 2 polymorphisms with an increased risk of
pyelonephritis in children [37]. We alsoexamined 5 polymorphisms
in CXCR2 since it is a receptor for CXCL-8. One polymorphism
(CXCR2_T997C) had no variation and was not examined further.
Finally, we examined 7 well-characterized TLR-pathway variants
since previous studies suggest that these SNPs are associated with
altered TLR gene function and susceptibility to different infections.
The polymorphisms include TLR1_G1805T (amino acid (AA)
change S602I), TLR2_G2258A (AA R753Q), TLR4_A896G (AA
D299G), TLR4_C1196T (AA T399I), TLR5_C1174T (AA
R392STOP), TIRAP_C539T (AA S180L), and TIRAP_C558T
(AA A186A) [57,58,59,60,61,62,63,64,65,66].
Polymorphism TLR2_2258A, a hyporesponsive allele, was
associated with high ASB in that such subjects were more likely to
have the minor 2258A allele than those without ASB (Table 2, high
vs no ASB, Odds Ratio (OR) 3.44 (95% CI: 1.65–7.17, P=0.001)).
To adjust for population heterogeneity, we analyzed data in the
Caucasian subgroup and found a similar association of
TLR2_G2258A with high ASB (Table S1, high vs no ASB, OR
3.17 (95% CI: 1.52–6.61, P=0.002)). When we examined ASB
caused by gram-negative uropathogens, the results were similar
Polymorphisms and ASB
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P=0.0003. Also Table S2). We next examined possible confound-
ing factors that might account for this association, including case
(rUTI or pyelonephritis) and control (no UTI history) status. A
logistic regression model with case-control status as a covariate
found a similar association of TLR2_G2258A with ASB caused by
gram-negative uropathogens (P=0.0004, data not shown). In
addition, we did not find any interaction between SNP
TLR2_G2258A with case-control status (P=0.964 for interaction).
We also found an association of polymorphisms
TLR1_G1805T with ASB in an unadjusted analysis (Table 2).
However, in the Caucasian subgroup, the TLR1 association was
not present (Table S1). We recently found that SNPs
TLR5_C1174T and TLR4_A896G were associated with different
UTI outcomes [49]. There was no association of these TLR
pathway polymorphisms with ASB status from all uropathogens
(Table 2). Two TLR4 SNPs were associated with ASB caused by
gram-positive organisms (Table 4). The biologic significance of this
Table 1. Demographic and microbiologic characteristics of ASB study groups.
Variable No ASB
a (N=731) Medium ASB (N=286) High ASB (N=105)
N( % )
a N( % )
a N( % )
a
Age at study enrollment, years (mean) 36.6 38.6 39.3
Ethnicity
b
American Indian/Alaska native 30 (4.1) 10 (3.5) 4 (3.8)
Asian 85 (11.6) 39 (13.6) 8 (7.6)
Black or African American 48 (6.6) 20 (7.0) 6 (5.7)
Native Hawaiian or Pacific Is. 13 (1.8) 9 (3.2) 2 (1.9)
Caucasian 567 (77.6) 212 (74.1) 89 (84.8)
Hispanic/Latino 56 (7.7) 17 (5.9) 9 (8.6)
Other 40 (5.5) 14 (4.9) 4 (3.8)
Health conditions (history of)
Kidney stones 29 (4.0) 19 (6.6) 6 (5.7)
Kidney failure/insufficiency 4 (0.6) 1 (0.4) 2 (1.9)
Diabetes (not during pregnancy) 12 (1.6) 15 (5.2)
c 5 (4.8)
d
Urinary Tract Procedure History
Bladder/kidney surgery 30 (4.10) 14 (4.90) 14 (13.33)
c
Cystoscopy 41 (5.61) 17 (5.94) 10 (9.52)
Microbiology
e
Gram-Negative Bacteria
E. coli: beta hemolytic 39 7
E. coli: non beta hemolytic 65 33
Enterobacter species 50
Proteus species 00
Proteus mirabilis 11 3
Klebsiella species 11 9
Citrobacter species 54
Morganella species 20
Other Gram-negative Rods
f 10
Gram-Positive Bacteria
Enterococcus species 160 53
Group B Streptococcus 53 13
Lactobacillus 19 22
Staphylococcus saprophyticus 01
Staphylococcus aureus 21
Staphylococcus, coagulase-negative
f 11
Mixed Gram Positive Flora (MGP)
f 638 0
aDefinitions: CFU/ml of uropathogen: No ASB ,10
3; Medium ASB: $10
3 & ,10
5; High ASB: $10
5.
bNumbers and percentages in ethnicity subcategories can be greater than total number due to selection of more than one category for an individual.
CP#0.01 or
d P#0.05, when compared to group with no ASB.
eFor microbiology, numbers without percentages listed. The number of samples without growth of a specific pathogen in the ‘‘No ASB’’ group is left blank since it is the
remainder of the 1122 individuals who had culture data available, but did not meet Medium or High ASB criteria.
fNot included in uropathogen definition for this study.
doi:10.1371/journal.pone.0008300.t001
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8300was not clear since TLR4 recognizes LPS, which is not present on
most gram-positive organisms.
We did not find any associations of CXCR1 or CXCR2
polymorphisms with ASB in the entire group or in the Caucasian
subgroup (Tables 2 and S1). However, several CXCR1 polymor-
phisms were associated with ASB caused by gram-positive
pathogens (Table 4, SNP T92G, for high ASB, OR 2.44 (95%
CI: 1.16–5.12, P=0.018; SNP C1003T, for high ASB, OR 2.28
(1.05–4.96), P=0.038); and SNP ZA11069G for all ASB, OR 0.51
(0.28–0.94), P=0.03)). Two of these associations remained
statistically significant when analyzed in the Caucasian only
subgroup (Table S3, SNP T92G, for high ASB, OR 2.34 (95% CI:
1.07–5.14, P=0.035; and SNP ZA11069G for all ASB, OR 0.51
(0.28–0.96), P=0.036)). One SNP showed a similar magnitude of
effect that was not statistically significant (SNP C1003T, for high
ASB, OR 2.10 (0.92–4.83), P=0.080). There were several
associations of CXCR1 polymorphisms with ASB caused by
gram-negative pathogens (Table 3). However, the biologic
significance of these latter associations was less clear since they
were only present at medium, but not high, levels of ASB. We also
examined whether CXCR1 or CXCR2 polymorphisms were
associated with a history of recurrent cystitis (rUTI) or pyelone-
phritis We did not find any significant associations in the entire
group or the Caucasian only subgroup (Tables S4 and S5).
Together, these results provide evidence that polymorphism
TLR2_G2258A is associated with ASB (all ASB as well as ASB
caused by gram-negative uropathogens) and CXCR1 is associated
with ASB caused by gram-positive uropathogens.
ASB Is Associated with Urine CXCL-8, but Not Other
Chemokines
To examine whether ASB is associated with chemokine levels,
we measured urine levels of CXCL-8, CXCL-5, CXCL-6, and
sICAM-1. We also examined IL-6, but only a small number of
women had detectable IL-6 levels (9 of 561during initial testing), so
no further measurement or analysis was performed. CXCL-8 was
associated with increasing levels of ASB (Table 5, P,0.001 when
comparing no ASB (90
th percentile value 55.7 pg/ml) vs. medium
ASB (102.6 pg/ml) vs. high ASB (249.3 pg/ml). This association
was present for ASB caused by both gram-negative as well as
gram-positive pathogens. We also examined CXCL-5, CXCL-6,
and sICAM-1 and found no difference in these outcomes by
womens’ ASB status. sICAM-1, in contrast to the other
chemokines, had high basal levels in women without ASB.
Together, these results suggest a selective association of ASB with
CXCL-8, but not CXCL-5, CXCL-6, or ICAM-1.
ASB, CXCL-6, and CXCL-8 Are Associated with Urine
Neutrophil Levels
We next examined whether ASB is associated with neutrophil
levels. ASB was associated with urine neutrophil levels with
statistically significant results when comparing positive vs. negative
levels of urine neutrophils (Table 6, OR 1.66 (95% CI: 1.14–2.41),
P=0.008). We also examined whether chemokines were associ-
ated with different neutrophil levels. CXCL-6 and CXCL-8 were
associated with increasing levels of urine neutrophils (Table 6,
P=0.0068 & P,0.0001, respectively). The magnitude of the effect
was most striking for CXCL-8 with 90
th percentile values ranging
from 32.5 pg/ml for those without urine neutrophils to
1578.3 pg/ml for those with high levels. CXCL-5 and sICAM-1
were not associated with urinary neutrophil levels. Together, these
results demonstrate that CXCL-6 and CXCL-8 levels, but not
CXCL-5 or sICAM-1, are associated with urine neutrophil levels.
CXCR1 Polymorphism Is Associated with Urine CXCL-8
Level
Finally, we examined whether DNA polymorphisms were
associated with urine chemokine levels in women with ASB.
One CXCR1 polymorphism (G827C) was associated with CXCL-
8 concentration in women with ASB from all uropathogens
(Table 7, P=0.004). Genotype GG was associated with lower
CXCL-8 (110.6 pg/ml 90
th percentile) in comparison to geno-
types GC or CC (385.6 pg/ml & 513.4 pg/ml, respectively)
(Figure 1). We also examined the association of CXCR1_G827C
in women with gram-negative and gram-positive ASB and found
similar differences (Figure 1). CXCR2_ZT13639C, had a
borderline association with CXCL-8 levels (P=0.05). No other
associations were found. Together, these results suggest a selective
association of candidate gene polymorphisms with chemokine
Table 5. ASB and urine chemokine levels.
Chemokine ASB Type 75th percentile value 90th percentile value P
no ASB (n=731) Medium ASB (n=286) High ASB (n=105) no ASB Medium ASB High ASB ASB
a
CXCL-8 (pg/ml) All 32.5 32.5 51.2 55.7 102.6 249.3 ,0.001
Gram2 32.5 32.5 101.3 60.8 120.7 395.0 0.004
Gram+ 32.5 32.5 32.5 71.3 99.6 126.6 0.0002
CXCL-5 (pg/ml) All 18.4 21.6 18.6 34.5 40.3 56.1 0.599
Gram2 18.1 22.2 29.5 36.9 33.4 62.0 0.707
Gram+ 19.1 22.2 16.1 35.4 44.5 19.4 0.436
CXCL-6 (pg/ml) All 24.8 20.2 25.9 56.3 44.6 67.1 0.758
Gram2 23.4 20.2 46.1 51.9 43.6 101.4 0.156
Gram+ 25.2 20.9 18.8 60.9 41.8 40.2 0.284
sICAM-1 (pg/ml) All 1132.9 1305.8 1278.7 1597.3 1808.5 1972.7 0.100
Gram2 1182.7 1242.5 1277.1 1643.1 1609.1 2015.4 0.630
Gram+ 1130.0 1305.8 1372.9 1602.9 1808.5 1972.7 0.067
aP value for comparison of 3 ASB clinical groups (no ASB vs medium vs high). P values or comparisons less than 0.05 are in bold.
doi:10.1371/journal.pone.0008300.t005
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PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8300levels, with the most robust association of a CXCR1 polymor-
phism with CXCL-8 concentrations in those with ASB.
Discussion
In this manuscript, we investigated the variation and genetic
regulation of inflammation associated with asymptomatic bacte-
riuria in women in order to gain insight into the early stages of
human UTI pathogenesis. Our main findings are that polymor-
phisms in TLR2 and CXCR1 are associated with ASB and that a
CXCR1 polymorphism is associated with urine CXCL-8 levels in
women with ASB. In addition, we found that chemokine levels are
selectively associated with ASB (CXCL-8, but not CXCL-5,
CXCL-6, or ICAM-1) and urinary neutrophil levels (CXCL-6 and
CXCL-8, but not CXCL-5 or sICAM-1.
There are several steps in UTI pathogenesis that could be
regulated by genetic variation of immune response genes. One of
the early steps is the establishment of bacteriuria, which often
occurs from ascent of bacteria from the colon, to the periurethral
region to the bladder. We found an association of TLR2_G2258A
Table 6. Urine neutrophil association with ASB and chemokine levels.
Urine Neutrophils
ASB Level Negative + ++ +++ Positive
b
,1000 (no ASB) 495 47 23 4 74
.=1000 242 35 20 5 60
OR (95% CI)
a 1.0 1.52 (0.96–2.42) 1.78 (0.96–3.30) 2.56 (0.68–9.60) 1.66 (1.14, 2.41)
P value 0.075 0.068 0.165 0.008
Chemokine Median/75%/90% P
c
CXCL-8 28.6/32.5/32.5 33.6/89.7/171.5 73.3/284.7/751.8 568.0/912.4/1578.3 ,0.0001
CXCL-5 16.1/18.0/36.1 16.1/24.6/47.0 16.1/20.3/42.2 16.1/80.0/188.7 0.0809
CXCL-6 16.1/20.2/43.6 16.1/39.2/66.4 16.1/36.0/254.3 48.9/153.3/289.5 0.0068
ICAM-1 453.8/1114.3/1602.9 682.9/1323.5/1604.8 430.9/1274.4/2161.9 979.7/1211.0/1418.9 0.1676
aComparing Urine PMNs in those with and without ASB with ‘‘negative’’ PMN group as reference.
bPositive=combination of +, ++,a n d+++ neutrophil counts.
cComparing chemokine values at different urine neutrophil levels.
doi:10.1371/journal.pone.0008300.t006
Table 7. CXCR1, CXCR2, and TLR polymorphisms and chemokine levels in women with ASB
a.
Gene & SNP Alleles CXCL-8 [pg/ml] CXCL-5 [pg/ml] CXCL-6 [pg/ml] sICAM-1 [pg/ml]
(major/minor) coefficient P coefficient P coefficient P coefficient P
CXCR1
rs3138060 C/G 15.21 0.488 22.70 0.674 4.83 0.730 42.87 0.669
T92G T/G 238.65 0.193 0.48 0.953 218.72 0.371 2225.38 0.089
G827C G/C 53.32 0.009 23.05 0.591 22.49 0.862 139.42 0.125
C1003T C/T 239.68 0.208 1.28 0.884 219.14 0.390 2187.06 0.186
ZA11069G G/A 238.99 0.252 22.54 0.789 215.21 0.527 203.50 0.181
CXCR2
ZC9316T C/T 252.72 0.176 1.58 0.884 43.79 0.108 252.36 0.751
C768T C/T 32.60 0.291 20.69 0.936 223.31 0.284 213.79 0.921
ZG12229A G/A 7.46 0.513 0.35 0.913 26.29 0.435 228.00 0.579
ZT13639C C/T 220.96 0.060 0.06 0.985 2.80 0.722 20.02 1.000
TLR Pathway
TLR1_G1805T G/T 8.68 0.468 21.12 0.737 23.98 0.634 59.18 0.240
TLR2-G2258A G/A 45.37 0.212 28.42 0.406 219.17 0.455 46.67 0.775
TLR4_A896G A/G 32.13 0.234 4.96 0.509 0.68 0.972 127.70 0.291
TLR4_C1196T C/T 24.48 0.420 3.38 0.690 2.78 0.897 22.28 0.987
TLR5_C1174T C/T 22.27 0.932 22.58 0.727 7.38 0.727 211.91 0.524
TIRAP_C539T C/T 10.20 0.533 1.19 0.795 13.72 0.234 263.19 0.389
TIRAP_C558T C/T 27.22 0.624 2.27 0.579 29.77 0.346 268.40 0.297
aWomen with ASB defined as those with .=1000 CFU/ml of a uropathogen. Chemokine levels were analyzed by genotype for each polymorphism with a log-additive
model.
doi:10.1371/journal.pone.0008300.t007
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PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8300with ASB. Interestingly, this SNP was not associated with a history
of rUTI or pyelonephritis in the same cohort [49]. Polymorphism
TLR2_2258A encodes an arginine to glutamine amino acid
change in the TIR signaling domain, mediates impaired signalling
in HEK293 cells transfected with TLR2 in an NF-kB assay, and is
associated with decreased cytokine production after ex vivo
stimulation of whole blood with Borrelia burgdorferi lysates [65].
This polymorphism has been associated with protection from
Lyme disease as well as increased susceptibility to tuberculosis
[65,67]. A previous study in children found an association of
TLR2_G2258A with ASB as well as symptomatic UTIs [47]. Our
results confirm these findings with ASB, but not cystitis,
susceptibility [49] (39). This apparent contrast in results may be
attributable to different study populations (children vs adults from
different ethnic backgrounds). Together, these findings suggest
that TLR2 signaling may impact susceptibility to human UTIs at
an early stage that regulates the establishment of bacteriuria.
In addition, we found a selective association of urinary
chemokine levels (CXCL-8, but not CXCL-5, CXCL-6, or
ICAM-1) with ASB. Even though CXCL-8, CXCL-5, and
CXCL-6 are ligands for CXCR1 and CXCR2, our data suggest
differential regulation of these chemokines in response to
bacteriuria. With at least 8 chemokines involved in neutrophil
chemotaxis, it is often difficult to elucidate specific and/or non-
redundant roles of individual chemokines. By focusing on ASB, we
attempted to discover which chemokines are involved with
neutrophil migration during early steps in UTI pathogenesis.
With progression of disease to a symptomatic stage, a different
pattern of elevated chemokines likely occurs. Previous studies of
urine chemokine levels have mainly focused on IL-6 and CXCL-8
during episodes of symptomatic cystitis [20,22,23,24,27]. We did
not confirm the findings of previous studies of ASB with urine IL-6
levels, but did confirm previous reports of elevated CXCL-8
[19,21]. Although urine CXCL-5 has been found to be elevated in
women with cystitis or urosepsis, it has not been examined in ASB
[26,28]. To our knowledge, CXCL-6, and sICAM-1 have not
been measured in previous studies of either symptomatic UTIs or
ASB. Further studies of additional chemokines during ASB and
other stages of disease should further elucidate the association of
specific chemokines with specific steps in UTI pathogenesis.
We also found a selective association of chemokines (CXCL-6,
and CXCL-8, but not CXCL-5 or sICAM-1) with urine
neutrophil levels. Previous studies demonstrated that urine
neutrophil counts are associated with elevated CXCL-8 levels
[25]. Depletion of CXCL-8 from urine decreased the chemotactic
activity by an average of 54.7%, suggesting that additional
chemokines are involved. Our data suggest that CXCL-6 is an
additional chemokine involved in chemotaxis of neutrophils to the
urine in the presence of bacteriuria. Interestingly, sICAM-1 was
not associated with elevated urine neutrophils. sICAM-1 may have
a different role in UTI pathogenesis, as it is expressed by
endothelial cells rather than bladder epithelium or neutrophils
[31]. sICAM-1 binds to MAC1 (CD11b-CD18) on neutrophils
and facilitates PMN slowing and subsequent migration from the
blood vessel lumen to the interstitial tissue [68]. With a different
cell source and bladder location, sICAM-1 likely mediates a
different step in PMN migration in comparison to CXCL-5,
CXCL-6, and CXCL-8.
We also found an association of several CXCR1 SNPs (T92G,
C1003T, and ZA11069G) with ASB caused by gram-positive
uropathogens. Furthermore, we found an association of polymor-
phism G827C in CXCR1 with CXCL-8 levels in women with
ASB. This polymorphism (also called variant 2 or 6334:L19592),
which encodes a serine to threonine substitution at amino acid
276, has previously been associated with risks of pyelonephritis
and vesicoureteral reflux in childhood [37]. The mechanism
underlying this association is not clear. One possibility is that
CXCR1 variants regulate recruitment of neutrophils to the
bladder in response to CXCL-8 produced by epithelial cells or
neutrophils. If reduced numbers of neutrophils migrate to the
bladder, then one source of CXCL-8 production will be
eliminated. Further studies of the effects of CXCR-1_G827C on
cyhemokine expression will be needed to clarify this mechanism.
Potential limitations of our study include effects of population
admixture and multiple comparisons. To account for possible
confounding effects from population heterogeneity, we performed
our genetic analyses in the Caucasian subgroup as well as the
entire cohort. Despite these attempts to minimize population
admixture effects, we cannot exclude this possibility. A second
possible limitation is the issue of multiple comparisons. As a matter
of hypothesis testing, we prioritized seven well-characterized TLR
pathway functional polymorphisms and 10 SNPs in the two major
receptors involved in neutrophil chemotaxis. SNPs with well-
characterized function do not generally have the same require-
ment for adjustments for multiple comparisons, due to a well-
founded a priori hypothesis of their potential association with a
cellular function. Even if a strict Bonferroni correction were taken
for the association of TLR2_G2258A with ASB, the adjusted P
value would remain significant at ,0.017 (17 polymorphisms x
,0.001 for high vs no ASB comparison). Regardless of which
adjustments are chosen for our data, convincing evidence of a
genetic effect ultimately requires replication studies as well as
detailed analysis of functional effects of each polymorphism.
Another limitation is that our cross-sectional study design does not
enable us to assess whether the ASB episodes in our population are
linked to a future occurrence of cystitis. We recently completed a
prospective study of women with recurrent cystitis that included
daily urine sampling prior to an episode of cystitis [69]. With such
a study design, it may be feasible to analyze whether genetic
variation and urine inflammatory profiles associated with ASB are
predictive of a subsequent cystitis episode.
Our study also has numerous strengths. First, to our knowledge
this is the largest study to examine associations of gene
polymorphisms and susceptibility to ASB, and is the only study
Figure 1. Association of a CXCR1 polymorphism with urine
CXCL-8 levels in women with ASB. Urine CXCL-8 levels in women
with ASB were stratified by CXCR1_G827C genotypes and analyzed by a
log-additive model. The 90
th percentile median values are plotted with
sample size for each genotype indicated.
doi:10.1371/journal.pone.0008300.g001
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population-based sampling strategy which increases the likelihood
that our findings are representative of the population. Finally, this
is the first study to examine the association of polymorphisms with
urine chemokine and neutrophil levels.
In summary, our results suggest that genetic variation of TLR
and chemokine pathways is associated with asymptomatic
bacteriuria and urine chemokine levels. Examining genetic
regulation of the urinary tract immune response during ASB
provides an opportunity to understand early events in pathogenesis
prior to the complex cytokine and chemokine inflammatory
cascades present during symptomatic cystitis episodes.
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